Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oncological Prognosis of Prostate Lesions by CEST MRI: Correlation of CEST MRI and Anatomopathological Analysis

NCT06669273 is registered in ClinicalTrials.gov with University Hospital, Clermont-Ferrand as lead sponsor.

NCT NCT06669273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06669273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oncological Prognosis of Prostate Lesions by CEST MRI: Correlation of CEST MRI and Anatomopathological Analysis
Lead sponsor
University Hospital, Clermont-Ferrand
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 31, 2024
Completion date
December 31, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

suspected prostate cancer (increased psa level)